arrow_back Back to App

Pharmaceutical Supply Chain Risk Assessment: Ensuring Drug Availability and National Security.

This Act mandates a comprehensive government assessment of the pharmaceutical supply chain to prevent drug shortages and protect public health. The goal is to identify essential medicines with vulnerable supply chains, especially those sourced internationally, and strengthen domestic manufacturing capabilities. This measure aims to ensure citizens have stable access to critical medications during emergencies and daily life.
Key points
The government must create a list of essential medicines and annually assess which ones have the most vulnerable supply chains, particularly those manufactured abroad.
The assessment will identify gaps in domestic drug production and threats, including cyberattacks, that could disrupt life-saving supplies.
The findings of the assessment, excluding sensitive information, will be made publicly available, increasing transparency regarding drug supply security.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_1961
Sponsor: Sen. Peters, Gary C. [D-MI]
Process start date: 2023-06-13
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pharmaceutical Supply Chain Risk Assessment Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_1961.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-06-13.

What are the main provisions?

Key points include:

  • The government must create a list of essential medicines and annually assess which ones have the most vulnerable supply chains, particularly those manufactured abroad.
  • The assessment will identify gaps in domestic drug production and threats, including cyberattacks, that could disrupt life-saving supplies.
  • The findings of the assessment, excluding sensitive information, will be made publicly available, increasing transparency regarding drug supply security.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Peters, Gary C. [D-MI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Security